STAT+: With a win in lung cancer, biotech’s wealthiest outsider surfs to new heights
On Sunday, a small biotech company called Summit Therapeutics won a remarkable victory, saying its experimental drug outperformed Merck’s Keytruda, the world’s best-selling drug, in non-small cell lung cancer, the disease that represents Keytruda’s biggest market.
On Sunday, a small biotech company called Summit Therapeutics won a remarkable victory, saying its experimental drug outperformed Merck’s Keytruda, the world’s best-selling drug, in non-small cell lung cancer, the disease that represents Keytruda’s biggest market.
By itself, Summit’s victory would be a dramatic story, although not an unheard of one in the unpredictable world of biotechnology. But it’s just the start. Because at the center of it is one of the industry’s most iconoclastic figures: Robert “Bob” Duggan, who became a billionaire after he bought up shares of another biotech company, Pharmacyclics, that was on the brink of failure, developed a breakthrough cancer drug, and sold the company to AbbVie for $21 billion.
Duggan, 80, is a living rebuke to a pharmaceutical industry self-image that is increasingly crafted in Cambridge, Mass. and San Francisco. Before Pharmacyclics, he had no drug industry experience, having worked in cookie stores and then surgical robots. He lacks a college degree, and is a practicing scientologist who told STAT in an interview that he reads the works of Scientology founder L. Ron Hubbard every day and who has in the past said he’d given the church more than $360 million. He speaks in long, dramatic arcs, often spelling out words, referencing their roots, or giving itemized lists.
7 months 3 days ago
Biotech, Business, Pharma, biotechnology, Cancer, drug development, Pharmaceuticals, STAT+
Breast Cancer Rises Among Asian American and Pacific Islander Women
Christina Kashiwada was traveling for work during the summer of 2018 when she noticed a small, itchy lump in her left breast.
She thought little of it at first. She did routine self-checks and kept up with medical appointments. But a relative urged her to get a mammogram. She took the advice and learned she had stage 3 breast cancer, a revelation that stunned her.
Christina Kashiwada was traveling for work during the summer of 2018 when she noticed a small, itchy lump in her left breast.
She thought little of it at first. She did routine self-checks and kept up with medical appointments. But a relative urged her to get a mammogram. She took the advice and learned she had stage 3 breast cancer, a revelation that stunned her.
“I’m 36 years old, right?” said Kashiwada, a civil engineer in Sacramento, California. “No one’s thinking about cancer.”
About 11,000 Asian American and Pacific Islander women were diagnosed with breast cancer in 2021 and about 1,500 died. The latest federal data shows the rate of new breast cancer diagnoses in Asian American and Pacific Islander women — a group that once had relatively low rates of diagnosis — is rising much faster than that of many other racial and ethnic groups. The trend is especially sharp among young women such as Kashiwada.
About 55 of every 100,000 Asian American and Pacific Islander women under 50 were diagnosed with breast cancer in 2021, surpassing the rate for Black and Hispanic women and on par with the rate for white women, according to age-adjusted data from the National Institutes of Health. (Hispanic people can be of any race or combination of races but are grouped separately in this data.)
The rate of new breast cancer cases among Asian American and Pacific Islander women under 50 grew by about 52% from 2000 through 2021. Rates for AAPI women 50 to 64 grew 33% and rates for AAPI women 65 and older grew by 43% during that period. By comparison, the rate for women of all ages, races, and ethnicities grew by 3%.
Researchers have picked up on this trend and are racing to find out why it is occuring within this ethnically diverse group. They suspect the answer is complex, ranging from cultural shifts to pressure-filled lifestyles — yet they concede it remains a mystery and difficult for patients and their families to discuss because of cultural differences.
Helen Chew, director of the Clinical Breast Cancer Program at UC Davis Health, said the Asian American diaspora is so broad and diverse that simple explanations for the increase in breast cancer aren’t obvious.
“It’s a real trend,” Chew said, adding that “it is just difficult to tease out exactly why it is. Is it because we’re seeing an influx of people who have less access to care? Is it because of many things culturally where they may not want to come in if they see something on their breast?”
There’s urgency to solve this mystery because it’s costing lives. While women in most ethnic and racial groups are experiencing sharp declines in breast cancer death rates, about 12 of every 100,000 Asian American and Pacific Islander women of any age died from breast cancer in 2023, essentially the same death rate as in 2000, according to age-adjusted, provisional data from the Centers for Disease Control and Prevention. The breast cancer death rate among all women during that period dropped 30%.
The CDC does not break out breast cancer death rates for many different groups of Asian American women, such as those of Chinese or Korean descent. It has, though, begun distinguishing between Asian American women and Pacific Islander women.
Nearly 9,000 Asian American women died from breast cancer from 2018 through 2023, compared with about 500 Native Hawaiian and Pacific Islander women. However, breast cancer death rates were 116% higher among Native Hawaiian and Pacific Islander women than among Asian American women during that period.
Rates of pancreatic, thyroid, colon, and endometrial cancer, along with non-Hodgkin lymphoma rates, have also recently risen significantly among Asian American and Pacific Islander women under 50, NIH data show. Yet breast cancer is much more common among young AAPI women than any of those other types of cancer — especially concerning because young women are more likely to face more aggressive forms of the disease, with high mortality rates.
“We’re seeing somewhere almost around a 4% per-year increase,” said Scarlett Gomez, a professor and epidemiologist at the University of California-San Francisco’s Helen Diller Family Comprehensive Cancer Center. “We’re seeing even more than the 4% per-year increase in Asian/Pacific Islander women less than age 50.”
Gomez is a lead investigator on a large study exploring the causes of cancer in Asian Americans. She said there is not yet enough research to know what is causing the recent spike in breast cancer. The answer may involve multiple risk factors over a long period of time.
“One of the hypotheses that we're exploring there is the role of stress,” she said. “We're asking all sorts of questions about different sources of stress, different coping styles throughout the lifetime.”
It’s likely not just that there’s more screening. “We looked at trends by stage at diagnosis and we are seeing similar rates of increase across all stages of disease,” Gomez said.
Veronica Setiawan, a professor and epidemiologist at the Keck School of Medicine of the University of Southern California, said the trend may be related to Asian immigrants adopting some lifestyles that put them at higher risk. Setiawan is a breast cancer survivor who was diagnosed a few years ago at the age of 49.
“Asian women, American women, they become more westernized so they have their puberty younger now — having earlier age at [the first menstrual cycle] is associated with increased risk,” said Setiawan, who is working with Gomez on the cancer study. “Maybe giving birth later, we delay childbearing, we don't breastfeed — those are all associated with breast cancer risks.”
Moon Chen, a professor at the University of California-Davis and an expert on cancer health disparities, added that only a tiny fraction of NIH funding is devoted to researching cancer among Asian Americans.
Whatever its cause, the trend has created years of anguish for many patients.
Kashiwada underwent a mastectomy following her breast cancer diagnosis. During surgery, doctors at UC Davis Health discovered the cancer had spread to lymph nodes in her underarm. She underwent eight rounds of chemotherapy and 20 sessions of radiation treatment.
Throughout her treatments, Kashiwada kept her ordeal a secret from her grandmother, who had helped raise her. Her grandmother never knew about the diagnosis. “I didn't want her to worry about me or add stress to her,” Kashiwada said. “She just would probably never sleep if she knew that was happening. It was very important to me to protect her.”
Kashiwada moved in with her parents. Her mom took a leave from work to help take care of her.
Kashiwada’s two young children, who were 3 and 6 at the time, stayed with their dad so she could focus on her recovery.
“The kids would come over after school,” she said. “My dad would pick them up and bring them over to see me almost every day while their dad was at work.”
Kashiwada spent months regaining strength after the radiation treatments. She returned to work but with a doctor’s instruction to avoid lifting heavy objects.
Kashiwada had her final reconstructive surgery a few weeks before covid lockdowns began in 2020. But her treatment was not finished.
Her doctors had told her that estrogen fed her cancer, so they gave her medicine to put her through early menopause. The treatment was not as effective as they had hoped. Her doctor performed surgery in 2021 to remove her ovaries.
More recently, she was diagnosed with osteopenia and will start injections to stop bone loss.
Kashiwada said she has moved past many of the negative emotions she felt about her illness and wants other young women, including Asian American women like her, to be aware of their elevated risk.
“No matter how healthy you think you are, or you're exercising, or whatever you're doing, eating well, which is all the things I was doing — I would say it does not make you invincible or immune,” she said. “Not to say that you should be afraid of everything, but just be very in tune with your body and what your body's telling you.”
Phillip Reese is a data reporting specialist and an associate professor of journalism at California State University-Sacramento.
This article was produced by KFF Health News, which publishes California Healthline, an editorially independent service of the California Health Care Foundation. Supplemental support comes from the Asian American Journalists Association-Los Angeles through The California Endowment.
KFF Health News is a national newsroom that produces in-depth journalism about health issues and is one of the core operating programs at KFF—an independent source of health policy research, polling, and journalism. Learn more about KFF.
USE OUR CONTENT
This story can be republished for free (details).
7 months 1 week ago
california, Multimedia, Race and Health, States, Cancer, Women's Health
The biotech news you missed this week
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Hello! Hope your weekend was a blissful one. Today, we talk about AbbVie’s outsize marketing spend, see how GLP-1s are impacting cancer rates, and more.
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Hello! Hope your weekend was a blissful one. Today, we talk about AbbVie’s outsize marketing spend, see how GLP-1s are impacting cancer rates, and more.
9 months 5 days ago
Biotech, Business, Health, Pharma, Politics, The Readout, Biotech, biotechnology, Cancer, drug development, drug prices, drug pricing, FDA, finance, genetics, government agencies, Pharmaceuticals, White House
Exclusive: European VC Forbion hires Dyne CEO, expands in US
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Good morning. Read on today for some exclusive hiring news and a retraction of a high-profile paper on cancer detection.
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Good morning. Read on today for some exclusive hiring news and a retraction of a high-profile paper on cancer detection.
9 months 2 weeks ago
Biotech, Business, Health, Pharma, Politics, The Readout, Biotech, biotechnology, Cancer, drug development, drug prices, drug pricing, FDA, finance, Medicare, Pharmaceuticals, Research
Melanoma patients reveal dramatic stories for Skin Cancer Awareness Month: ‘I thought I was careful’
Skin cancer is the most common type of cancer in the U.S. — with one in five Americans developing the disease by the age of 70.
Melanoma is the deadliest form of skin cancer, expected to take the lives of more than 8,200 people in the U.S. this year.
Skin cancer is the most common type of cancer in the U.S. — with one in five Americans developing the disease by the age of 70.
Melanoma is the deadliest form of skin cancer, expected to take the lives of more than 8,200 people in the U.S. this year.
This May, for Skin Cancer Awareness Month, two melanoma patients are sharing their stories of how they overcame this invasive form of the disease.
SKIN CANCER CHECKS AND SUNSCREEN: WHY THESE (STILL) MATTER VERY MUCH FOR GOOD HEALTH
One even wrongly assumed that what she was experiencing "was just a normal part of aging and sun exposure." Here's what others can learn.
Melanoma is a type of skin cancer that starts in the melanocytes, which are the cells that produce the skin’s pigmentation (color).
Most cases — but not all — are caused by exposure to ultraviolet light. Melanoma can affect people of all skin tones and types.
"Melanoma is one of the most common type of cancer in younger patients," Nayoung Lee, M.D., assistant professor of dermatology at NYU Langone Health, told Fox News Digital.
The prognosis is "very good" when melanoma is detected early, but the survival rate falls steeply when it is detected at a more advanced stage, she noted.
"Melanoma can spread through the bloodstream to your lymph nodes and distant organs, so it is crucial to do regular skin exams to try to catch it at an early stage," Lee said.
Abby Weiner, 43, a wife and mother of three young boys living in Washington, D.C., had always been careful about protecting her skin from the sun — which is why her Oct. 2023 melanoma diagnosis was such a shock, she said.
"I had a spot on my cheek that started as a freckle and began getting darker and larger," she told Fox News Digital.
"I assumed it was just a normal part of aging and sun exposure."
VACCINE FOR DEADLY SKIN CANCER SHOWS ‘GROUNDBREAKING’ RESULTS IN CLINICAL TRIAL
Weiner’s sister encouraged her to get it checked out — which led to a biopsy and diagnosis.
"I was obviously shocked and frightened at first," said Weiner.
Her melanoma was removed using Mohs surgery, a procedure in which thin layers of skin are removed one at a time.
"I required two procedures to remove the cancer and surrounding margins," she said. "Now, most people don't even know I had surgery."
To others, Weiner’s advice is to remember to seek shade, wear sun-protective clothing, and apply a broad-spectrum, water-resistant sunscreen with an SPF of 30 or higher on a daily basis all year long.
"I thought I was careful about protecting myself from sun exposure by wearing a hat or applying sunscreen when my family was at the pool or planning to be outdoors — but if we were eating outdoors and there wasn't a table in the shade, I would end up sitting in the sun."
Now, Weiner said she will wait a little longer for a shaded table, and she always keeps a hat and sunscreen with her.
"My sons used to have difficulty applying sunscreen and wearing hats, but now that they've seen the impact skin cancer had on me, they are more cooperative," she said.
CANCER SCREENINGS: HERE ARE 5 TYPES AND CRITICAL INFORMATION TO KNOW ABOUT EACH
Weiner also recommends that everyone gets yearly skin checks with a board-certified dermatologist.
"I have so many friends — and even my sister, who probably saved my life — who didn't regularly see a dermatologist for a yearly skin check before they learned about my melanoma."
Steve Murray, 68, of the greater Washington, D.C. area, has worked in construction for several decades.
During his childhood, Murray spent summers at the beach in Ocean City, New Jersey, and winter visits to Florida, where he was exposed to the sun and didn’t do much to protect himself.
In the late 1990s, Murray was diagnosed with basal cell carcinoma, the most common type of skin cancer, and squamous cell carcinoma, a variation of skin cancer that tends to develop in people who have had a lot of sun exposure.
In 2008, he was diagnosed with melanoma.
"My initial symptoms included itching and scaling on my head, followed by irritation," he told Fox News Digital.
"Then there was discoloration and irregularity in the shape of my moles."
Initially, Murray feared the worst — "mainly death" — but his dermatologist determined that the melanoma was only on his scalp and hadn’t traveled to his lymph nodes.
Like Weiner, Murray had Mohs surgery to get rid of the cancer — and he was cleared.
VIRGINIA HIGH SCHOOL STUDENT CREATES SOAP TO FIGHT SKIN CANCER, IS AWARDED $25K: 'REMARKABLE EFFORT'
Since that diagnosis, Murray has had several more bouts of skin cancer.
In 2024, he underwent two surgeries for squamous cell carcinoma on his hand and back.
Now, Murray visits the dermatologist every three to six months. Also, he always wears a hat, sunscreen and long sleeves whenever possible to protect himself from the sun.
Murray’s advice to others is to make sun protection a priority when outdoors.
"You don’t notice at the time of initial exposure, but it haunts you later in life when you start developing pre-cancers and skin cancers like squamous cell carcinoma and melanoma that require immediate attention," he told Fox News Digital.
"Capturing these pre-cancers and cancers of the skin must be diagnosed early with regular checkups," he added. "Failure to do so could lead to death."
Dr. Lee of NYU Langone Health shared five tips to help prevent potentially deadly skin cancers like melanoma.
"Avoiding a burn is really only half the battle — there is no such thing as a base tan," Lee said. "Damaged skin is damaged skin."
For a safer way to achieve a sun-kissed glow on your first beach day of the summer, Lee recommends using self-tanning products.
When applying sunscreen, Lee recommends using 1 ounce, which would fill a shot glass.
IF YOU OR YOUR CHILDREN HAVE FRECKLES, HERE'S WHAT YOUR SKIN IS TRYING TO TELL YOU
"It should have a sun protection factor (SPF) of 30 and say ‘broad-spectrum’ on the label, which protects against the sun’s UVA and UVB rays," she said.
Reapply at least every 80 minutes, or more often if you’re sweating or swimming.
Physical sunscreen contains zinc or titanium, which is superior in efficacy to chemical sunscreen, according to Lee.
"Check your skin regularly so you know what’s normal and to notice any changes or new growths," Lee advised.
"Seek a dermatologist’s evaluation if you notice a changing, bleeding or persistently itchy spot."
This is the best way to determine if any mole or blemish is cancerous, according to Lee.
The ABCDE rule tells you what to look for when examining your skin.
CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER
The A stands for asymmetrical. "Noncancerous moles are typically symmetrical," Lee said.
B is for border, as the border of a cancerous spot or mole may be irregular or blurred.
C stands for color. "A typical mole tends to be evenly colored, usually a single shade of brown," Lee noted.
"Not all melanomas are dark and scary-appearing. They can be amelanotic, which means they can be more skin colored or pink."
D stands for diameter of the spot or mole, which may be a warning sign if it’s larger than 6 millimeters, according to Lee.
If the spot is evolving, which is what E stands for, it might be of concern.
Lee added, "Because melanomas can vary in appearance, it is important to see a dermatologist regularly for skin exams if you have a history of significant sun exposure, have many atypical appearing moles, or a family or personal history of melanoma so that you have an experienced set of eyes looking at any spots of concern."
10 months 4 weeks ago
Health, Cancer, skin-cancer, beauty-and-skin, healthy-living, lifestyle, health-care
Innovation Doesn’t Always Have To Involve The Latest Tech, MD Anderson Exec Says
While adopting new technology is obviously a big part of healthcare innovation teams’ work, there are plenty of worthwhile initiatives that don’t involve advanced technologies, pointed out Dan Shoenthal, chief innovation officer at MD Anderson Cancer Center.
While adopting new technology is obviously a big part of healthcare innovation teams’ work, there are plenty of worthwhile initiatives that don’t involve advanced technologies, pointed out Dan Shoenthal, chief innovation officer at MD Anderson Cancer Center.
The post Innovation Doesn’t Always Have To Involve The Latest Tech, MD Anderson Exec Says appeared first on MedCity News.
10 months 4 weeks ago
Health Tech, Hospitals, Providers, Cancer, innovation, MD Anderson, MD Anderson Cancer Center, patient experience, Reuters Events, University of Texas MD Anderson Cancer Center
Opinion: Colorectal cancer is increasing among young people. It’s time to boost research on it
I am not writing here to talk about my husband, Chadwick Boseman, who died far too young from colorectal cancer. I am not here to give any glimpses into our obviously private life and his obviously private battle with this cancer, which is affecting far more young lives than it should.
The legacy he created is not about cancer and I hope you don’t remember him that way. Instead, remember him for his work. Remember him as Chadwick Boseman the actor, the writer, the leader, the inspiration.
11 months 2 weeks ago
First Opinion, Cancer, Research
AI could predict whether cancer treatments will work, experts say: ‘Exciting time in medicine'
A chemotherapy alternative called immunotherapy is showing promise in treating cancer — and a new artificial intelligence tool could help ensure that patients have the best possible experience.
A chemotherapy alternative called immunotherapy is showing promise in treating cancer — and a new artificial intelligence tool could help ensure that patients have the best possible experience.
Immunotherapy, first approved in 2011, uses the cancer patient’s own immune system to target and fight cancer.
While it doesn’t work for everyone, for the 15% to 20% who do see results, it can be life-saving.
WHAT IS ARTIFICIAL INTELLIGENCE (AI)?
Like any medication, immunotherapy has the potential for adverse side effects — which can be severe for some.
Studies show that some 10% to 15% of patients develop "significant toxicities."
Headquartered in Chicago, GE HealthCare — working in tandem with Vanderbilt University Medical Center (VUMC) in Nashville, Tennessee — has created an AI model that's designed to help remove some of the uncertainties surrounding immunotherapy.
Over the five years it’s been in development, the AI model was trained on thousands of patients’ electronic health records (EHRs) to recognize patterns in how they responded to immunotherapy, focusing on safety and effectiveness.
AI MODEL COULD HELP PREDICT LUNG CANCER RISKS IN NON-SMOKERS, STUDY FINDS: ‘SIGNIFICANT ADVANCEMENT’
"The model predicts which patients are likely to derive the benefit from immunotherapy versus those patients who may not," said Jan Wolber, global digital product leader at GE HealthCare’s pharmaceutical diagnostics segment, in an interview with Fox News Digital.
"It also predicts which patients have a likelihood of developing one or more significant toxicities."
When pulling data from the patient’s health record, the model looks at demographic information, preexisting diagnoses, lifestyle habits (such as smoking), medication history and more.
"All of these data are already being collected by the patient’s oncologist, or they’re filling out a form in the waiting room ahead of time," said Travis Osterman, a medical oncologist and associate chief medical information officer at Vanderbilt University Medical Center, in an interview with Fox News Digital.
(Osterman is working with Wolber on the development of the AI model.)
BREAST CANCER BREAKTHROUGH: AI PREDICTS A THIRD OF CASES PRIOR TO DIAGNOSIS IN MAMMOGRAPHY STUDY
"We're not asking for additional blood samples or complex imaging. These are all data points that we're already collecting — vital signs, diagnoses, lab values, those sorts of things."
In a study, the AI model showed 70% to 80% accuracy in predicting patients’ responses to immunotherapies, according to an article published in the Journal of Clinical Oncology Clinical Cancer Informatics.
"While the models are not perfect, this is actually a very good result," Wolber said. "We can implement those models with very little additional effort because there are no additional measurements required in the clinic."
This type of technology is "a natural progression of what we've been doing in medicine for a very long time," Osterman said.
"The only difference is, instead of surveying patients, we're taking the entirety of the medical record and looking for risk factors that contribute to an outcome," he said in an interview with Fox News Digital.
With immunotherapy, there is generally a lower response rate than with chemotherapy, Osterman noted — but some patients have "incredible responses" and ultimately become cancer-free.
"I would be horrified to know that one of my patients that I didn't give immunotherapy to could have been one of the tremendous responders," he told Fox News Digital.
Conversely, Osterman noted that in rare cases, immunotherapy can have some serious side effects.
"I would say about half of patients don't have any side effects, but for those who do, some of them are really life-altering," he said.
"We don't want to miss anyone, but we also don't want to harm anyone."
At the core of the AI project, Osterman said, is the ability to "put all the information into the exam room," so the oncologist can counsel the patient about the risks and benefits of this particular therapy and make the best, most informed decision about their care.
Dr. Marc Siegel, clinical professor of medicine at NYU Langone Medical Center and a Fox News medical contributor, was not involved in the AI model’s development but commented on its potential.
"AI models are emerging that are helping to manage responses to cancer treatments," he told Fox News Digital.
"These can allow for more treatment options and be more predictive of outcome."
AI models like this one are an example of "the essential future of personalized medicine," Siegel said, "where each patient is approached differently and their cancer is analyzed and treated with precision using genetic and protein analysis."
As long as physicians and scientists remain in charge — "not a computer or robot" — Siegel said that "there is no downside."
The AI model does carry some degree of limitations, the experts acknowledged.
"The models obviously do not return 100% accuracy," Wolber told Fox News Digital. "So there are some so-called false positives or false negatives."
NEW AI ‘CANCER CHATBOT’ PROVIDES PATIENTS AND FAMILIES WITH 24/7 SUPPORT: 'EMPATHETIC APPROACH'
The tool is not a "black box" that will provide a surefire answer, he noted. Rather, it's a tool that provides data points to the clinician and informs them as they make patient management decisions.
Osterman pointed out that the AI model uses a "relatively small dataset."
"We would love to be able to refine our predictions by learning on bigger data sets," he said.
The team is currently looking for partnerships that will enable them to test the AI model in new settings and achieve even higher accuracy in its predictions.
Another challenge, Osterman said, is the need to integrate these AI recommendations into the workflow.
"This is pretty new for us as a health care community, and I think we're all going to be wrestling with that question," he said.
CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER
Looking ahead, once the AI model has achieved the necessary regulatory approvals, GE HealthCare plans to make the technology available for widespread use by clinicians — perhaps even expanding to other care areas, such as neurology or cardiology.
There is also the potential to incorporate it into drug development.
"One of the things that drug makers struggle with is that some of the agents that may be really useful for some patients could be really toxic for others," Osterman said.
"If they were able to pick which patients could go into a trial and exclude patients with the highest risk of toxicity, that could mean the difference between that drug being made available or not."
He added, "If this means that we're able to help tailor that precision risk to patients, I'm in favor of that."
Ultimately, Osterman said, "it's a really exciting time to be in medicine … I think we're going to look back and regard this as the golden age of AI recommendations. I think they're probably here to stay."
11 months 3 weeks ago
Health, Cancer, cancer-research, artificial-intelligence, medical-tech, lifestyle, health-care, medications, medical-research
En California, la cobertura de salud ampliada a inmigrantes choca con las revisiones de Medicaid
OAKLAND, California – El Medi-Cal llegó a Antonio Abundis cuando el conserje más lo necesitaba.
Poco después que Abundis pasara de tener cobertura limitada a una cobertura completa en 2022, bajo la expansión del Medi-Cal de California para adultos mayores sin papeles, fue diagnosticado con leucemia, un tipo de cáncer que afecta las células de la sangre.
OAKLAND, California – El Medi-Cal llegó a Antonio Abundis cuando el conserje más lo necesitaba.
Poco después que Abundis pasara de tener cobertura limitada a una cobertura completa en 2022, bajo la expansión del Medi-Cal de California para adultos mayores sin papeles, fue diagnosticado con leucemia, un tipo de cáncer que afecta las células de la sangre.
El padre de tres hijos, de voz suave, tomó la noticia con calma cuando su médico le dijo que sus análisis de sangre sugerían que su cáncer no estaba en una etapa avanzada. Sus siguientes pasos fueron hacerse más pruebas y tener un plan de tratamiento con un equipo de cáncer en Epic Care, en Emeryville.
Pero todo eso se fue por la borda cuando se presentó en julio pasado para hacerse un análisis de sangre en La Clínica de La Raza en Oakland, y le dijeron que ya no era beneficiario de Medi-Cal.
“Nunca mandaron una carta ni nada de que a mí me la había negado”, dijo Abundis, ahora de 63 años, sobre la pérdida de su cobertura.
Abundis es uno de los cientos de miles de latinos de California que han sido expulsados de Medi-Cal —el programa estatal de Medicaid para personas de bajos ingresos— a medida que los estados reanudaban las verificaciones de elegibilidad, que se habían suspendido en el punto más álgido de la pandemia de covid-19.
El proceso de redeterminación ha afectado de forma desproporcionada a los latinos, que constituyen la mayoría de los beneficiarios de Medi-Cal.
Según el Departamento de Servicios de Salud de California (DHCS), más de 613,000 de los 1,24 millones de residentes que fueron dados de baja se identifican como latinos. Algunos, incluido Abundis, habían obtenido la cobertura poco tiempo antes, cuando el estado comenzó a expandir Medi-Cal para ofrecer cobertura a inmigrantes indocumentados.
El choque entre las políticas estatales y las federales no sólo ha significado un duro golpe para los beneficiarios: también disparó la demanda de asistencia para realizar los trámites de inscripción.
Esto ocurre porque muchas personas son excluidas de Medi-Cal por cuestiones administrativas.
Los grupos de salud que trabajan con las comunidades latinas informan que están inundados de solicitudes de ayuda. Al mismo tiempo, una encuesta patrocinada por el estado sugiere que los hogares hispanos tienen más probabilidades que otros grupos étnicos o raciales de perder la cobertura porque tienen menos información sobre el proceso de renovación.
También pueden tener dificultades para defenderse por sí solos.
Algunos defensores de salud están presionando para que haya una pausa en este proceso. Advierten que las desafiliaciones no solo socavarán los esfuerzos del estado para reducir el número de personas sin seguro, sino que podrían exacerbar las disparidades en salud, especialmente para un grupo étnico que sufrió fuerte el peso de la pandemia.
Un estudio nacional encontró que los latinos en el país tuvieron tres veces más probabilidades de desarrollar covid y el doble de probabilidades de morir a causa de la enfermedad que la población en general, en parte porque tienden a vivir en hogares más hacinados o multigeneracionales y tienen trabajos en servicios, de cara al público.
“Estas dificultades nos colocan a todos como comunidad en un estatus más frágil, en el cual la red de seguridad es aún más significativa”, dijo Seciah Aquino, directora ejecutiva de la Latino Coalition for a Healthy California, una organización de defensa de salud.
La asambleísta Tasha Boerner (demócrata de Encinitas) ha presentado un proyecto de ley que desaceleraría las bajas permitiendo que las personas de 19 años o más mantengan automáticamente su cobertura durante 12 meses, y extendiendo las políticas flexibles de la era pandémica, como no requerir prueba de ingresos para renovar la cobertura en ciertos casos. Esto beneficiaría a los hispanos, que representan casi el 51% de la población de Medi-Cal en comparación con el 40% de la población total del estado.
La oficina del gobernador dijo que no comenta sobre proyectos legislativos que están aún en proceso.
Tony Cava, vocero del Departamento de Servicios de Atención Médica (DHCS), dijo en un correo electrónico que la agencia ha tomado medidas para aumentar el número de personas reinscritas automáticamente en Medi-Cal y no cree que sea necesaria una pausa. La tasa de desafiliación disminuyó un 10% de noviembre a diciembre, apuntó Cava.
Sin embargo, funcionarios estatales reconocen que se podría hacer más para ayudar a las personas a completar sus solicitudes. “Todavía no estamos llegando a ciertos sectores”, dijo Yingjia Huang, subdirectora adjunta de beneficios de atención médica y elegibilidad del DHCS.
California fue el primer estado en ampliar la elegibilidad de Medicaid a todos los inmigrantes que calificaran, sin importar su estatus migratorio, implementándolo gradualmente durante varios años: niños en 2016, adultos jóvenes de 19 a 26 años en 2020, personas de 50 años en adelante en 2022, y todos los adultos restantes este año.
Pero California, como otros estados, reanudó las verificaciones de elegibilidad en abril pasado, y se espera que el proceso continúe hasta mayo. El estado ahora está viendo que las tasas de desafiliación vuelven a los niveles previos a la pandemia, o el 19%-20% de la población de Medi-Cal cada año, según el DHCS.
Jane García, directora ejecutiva de La Clínica de La Raza, testificó ante el Comité de Salud de la Junta de Supervisores del condado de Alameda que las desafiliaciones siguen siendo un desafío, justo cuando su equipo intenta inscribir a residentes recién elegibles. “Es una carga enorme para nuestro personal”, les dijo a los supervisores en enero.
Aunque muchos beneficiarios ya no califican porque sus ingresos aumentaron, muchos más han sido eliminados de los registros por no responder a avisos o devolver documentos. En muchos casos, los paquetes de documentos para renovar la cobertura se enviaron a direcciones antiguas. Muchos se enteran de que perdieron la cobertura recién cuando van al médico.
“Sabían que algo estaba pasando”, dijo Janet Anwar, gerenta de elegibilidad en el Tiburcio Vásquez Health Center, en East Bay. “No sabían exactamente qué era, cómo los iba a afectar hasta que llegó el día y fueron desafiliados. Y estaban haciéndose un chequeo, o programando una cita, y luego… ‘Oye, perdiste tu cobertura'”.
Y la reinscripción es un desafío. Una encuesta patrocinada por el estado publicada el 12 de febrero por la California Health Care Foundation halló que el 30% de los hogares hispanos intentaron completar un formulario de renovación sin suerte, en comparación con el 19% de los hogares blancos no hispanos. Y el 43% de los hispanos informaron que les gustaría volver a comenzar con Medi-Cal, pero no sabían cómo, en comparación con el 32% de las personas en hogares blancos no hispanos.
La familia Abundis está entre las que no saben dónde obtener respuestas a sus preguntas. Aunque la esposa de Abundis envió la documentación de renovación de Medi-Cal para toda la familia en octubre, ella y dos hijos que aún viven con ellos pudieron mantener la cobertura; Abundis fue el único que la perdió.
No ha recibido una explicación de por qué lo sacaron de Medi-Cal ni ha sido notificado de cómo apelar o volver a solicitarlo.
Ahora se preocupa de que tal vez no califique por sí solo según sus ingresos anuales de aproximadamente $36,000, ya que el límite es de $20,121 para un individuo, pero de $41,400 para una familia de cuatro.
Es probable que un navegador pueda verificar si él y su familia califican como hogar para Medi-Cal. Covered California, el mercado de seguros de salud estatal, ofrece planes privados que pueden costar menos de $10 al mes en primas y permite una inscripción especial cuando las personas pierden Medi-Cal o la cobertura del empleador. Pero los inmigrantes que no viven legalmente en el estado no califican para los subsidios de Covered California. Abundis supone que no podrá pagar las primas ni los copagos, por lo que no presentó la solicitud.
Pero Abundis supone que no podrá pagar primas o copagos, así que no ha presentado una solicitud.
Abundis, quien visitó a un médico por primera vez en mayo de 2022 debido a una fatiga sin causa aparente, dolor constante en la espalda y las rodillas, falta de aliento y pérdida de peso inexplicable, teme no poder pagar la atención médica. La Clínica de La Raza, el centro de salud comunitario en donde le hicieron análisis de sangre, lo ayudó ese día a que no tuviera que pagar por adelantado, pero desde entonces dejó de buscar atención médica.
Más de un año después de su diagnóstico, todavía no sabe en qué etapa del cáncer se encuentra ni cuál debería ser su plan de tratamiento. Aunque la detección temprana del cáncer puede aumentar las posibilidades de supervivencia, algunos tipos de leucemia avanzan rápidamente. Sin más pruebas, Abundis no conoce su pronóstico.
Yo estoy mentalizado”, dijo Abundis sobre su cáncer. “Lo que pase, pase”.
Incluso aquellos que buscan ayuda se topan con desafíos. Marisol, una inmigrante mexicana sin papeles, de 53 años, que vive en Richmond, California, intentó restablecer la cobertura durante meses. Aunque el estado experimentó una caída del 26% en las bajas de diciembre a enero, la proporción de latinos a los que se les canceló la cobertura durante ese período permaneció casi igual, lo que sugiere que enfrentan más barreras para la renovación.
Marisol, quien pidió que se usara su nombre de pila por temor a la deportación, también calificó para la cobertura completa de Medi-Cal durante la expansión estatal a todos los inmigrantes de 50 años en adelante.
En diciembre, recibió un paquete informándole que los ingresos de su hogar excedían el umbral de Medi-Cal, algo que ella creyó que era un error. El esposo de Marisol está sin trabajo debido a una lesión en la espalda, dijo, y sus dos hijos mantienen a su familia principalmente con trabajos de medio tiempo en Ross Dress for Less.
Ese mes, Marisol visitó una sucursal de Richmond del Departamento de Empleo y Servicios Humanos del condado de Contra Costa, con la esperanza de hablar con un navegador. En cambio, le dijeron que dejara su documentación y que llamara a un número de teléfono para verificar el estatus de su solicitud.
Desde entonces, llamó muchas veces y pasó horas en espera, pero no ha podido hablar con nadie. Los funcionarios del condado reconocieron tiempos de espera más prolongados debido al aumento de llamadas, y dijeron que el tiempo promedio es de 30 minutos.
“Entendemos la frustración de los miembros de la comunidad cuando a veces tienen dificultades para comunicarse”, escribió la vocera Tish Gallegos en un correo electrónico. Gallegos señaló que el centro de llamadas aumenta la dotación de personal durante las horas pico.
Después que El Tímpano contactara al condado para hacer comentarios, Marisol dijo que un trabajador de elegibilidad la contactó, y le explicó que su familia fue dada de baja porque sus hijos habían presentado impuestos por separado, por lo que el sistema de Medi-Cal determinó su elegibilidad individualmente en lugar de como familia.
El condado reintegró a Marisol y a su familia el 15 de marzo. Marisol dijo que recuperar Medi-Cal fue un final alegre pero agridulce para una lucha de meses, especialmente sabiendo que otras personas son desafiliadas por cuestiones de procedimiento. “Tristemente, tiene que haber presión para que arreglen algo”, dijo.
Jasmine Aguilera de El Tímpano está participando de la Journalism & Women Symposium’s Health Journalism Fellowship, apoyada por The Commonwealth Fund. Vanessa Flores, Katherine Nagasawa e Hiram Alejandro Durán de El Tímpano colaboraron con este artículo.
[Corrección: este artículo se actualizó a la 1:30 pm (ET), el 26 de marzo de 2024, para corregir los detalles sobre la elegibilidad para recibir asistencia financiera para pagar las primas de los seguros. Los inmigrantes que no viven legalmente en California no califican para los subsidios de Covered California].
KFF Health News is a national newsroom that produces in-depth journalism about health issues and is one of the core operating programs at KFF—an independent source of health policy research, polling, and journalism. Learn more about KFF.
USE OUR CONTENT
This story can be republished for free (details).
1 year 2 weeks ago
Health Care Costs, Insurance, Medi-Cal, Medicaid, Noticias En Español, Race and Health, States, Uninsured, Cancer, Latinos, Out-Of-Pocket Costs
How red and processed meats contribute to cancer
The Grenada Food and Nutrition Council advises choosing lean cuts of fresh meat and poultry, limiting red meats, eating more fish and adding plenty of plant-based proteins several times a week
View the full post How red and processed meats contribute to cancer on NOW Grenada.
1 year 1 month ago
Health, PRESS RELEASE, Cancer, cancer research uk, carcinogens, gfnc, grenada food and nutrition council, haem, who, world health organisation